Guardant Health Soars: FDA's Breakthrough Designation Boosts Stocks!

Guardant Health, Inc. rose 2.24% in intraday trading, with the company announcing that its Shield multi-cancer detection (MCD) test has been granted Breakthrough Device designation from the U.S. Food and Drug Administration (FDA). The Shield MCD test is a methylation-based blood test for the multi-cancer screening of multiple cancer types, including bladder, colorectal, esophageal, gastric, liver, lung, ovarian, and pancreas cancer in individuals aged 45 or older who are at typical average risk for cancer.